Review and Guide,GLP-1 and GLP-2 are secreted in response to nutrient ingestion

The question of why are glucagon-like peptides like glucagon delves into the intricate world of hormones and their impact on our bodies, particularly in regulating blood sugar. While they share structural similarities and a common precursor, glucagon and glucagon-like peptide-1 (GLP-1) have distinct, and often opposing, roles in glucose homeostasis. Understanding these differences is crucial, especially given the therapeutic applications of GLP-1 in conditions like type 2 diabetes.

At their core, both glucagon and GLP-1 are peptide hormones. Glucagon is a 29-amino acid peptide synthesized and secreted from the alpha (α) cells of the pancreas. Its primary function is to increase blood glucose levels when they drop too low, a state known as hypoglycemia. It achieves this by signaling the liver to break down stored glycogen into glucose and releasing it into the bloodstream. This action is essential for maintaining a steady supply of energy to the brain and other vital organs.

On the other hand, glucagon-like peptide-1 (GLP-1) is a hormone produced in the gut, specifically in the L-cells of the intestines, and is released in response to nutrient ingestion. It's derived from the tissue-specific posttranslational processing of the proglucagon gene, which explains its "glucagon-like" designation and the inherent structural resemblance to glucagon. However, despite this shared ancestry, GLP-1 and glucagon have largely opposing roles in glucose metabolism.

One of the most significant ways GLP-1 differs from glucagon is its effect on insulin secretion. While glucagon raises blood sugar, GLP-1 acts to lower it. It does this by potently stimulating insulin release from the beta (β) cells of the pancreas. This insulin release is glucose-dependent, meaning it primarily occurs when blood glucose levels are elevated, such as after a meal. This "glucose-dependent" nature is a key safety feature, reducing the risk of hypoglycemia compared to hormones that stimulate insulin release indiscriminately. Furthermore, GLP-1 potently inhibits glucagon secretion. This paracrine effect on the islets, potentially mediated by somatostatin, further contributes to lowering blood glucose levels after nutrient intake.

The physiological actions of GLP-1 extend beyond insulin regulation. It also slows gastric emptying, the process by which food leaves the stomach. This slower passage of food into the small intestine contributes to a more gradual absorption of nutrients, preventing sharp spikes in blood glucose. Additionally, GLP-1 is known to promote satiety and increase energy expenditure, which can contribute to weight management. In fact, GLP-1 plays a key role in the occurrence and development of metabolic diseases such as obesity and nonalcoholic fatty liver disease.

The therapeutic potential of GLP-1 has led to the development of Glucagon-like peptide-1 (GLP-1) agonists, also known as GLP-1 agonists or GLP-1 receptor agonists. These medications are designed to mimic the effects of the natural gut hormone GLP-1. They are primarily utilized to treat type 2 diabetes mellitus (T2DM) and obesity. Medications like Ozempic or Wegovy are prominent examples of this class. These GLP-1 drugs work by activating the GLP-1 receptor, triggering insulin release and reducing glucose levels, much like the natural hormone. Some medications in this group also act like another incretin hormone called gastric inhibitory polypeptide (GIP), further enhancing their glucose-lowering effects.

It's important to distinguish between the natural hormone and the medications. While GLP-1 drugs mimic the effects of a natural hormone our bodies produce called glucagon-like peptide-1, they are not the same as the hormone itself. The FDA has issued concerns about unapproved versions of GLP-1 drugs being used for weight loss, highlighting the importance of using regulated and prescribed medications.

In summary, while glucagon-like peptides share a common origin with glucagon, their functions in glucose regulation are remarkably different. Glucagon raises blood sugar, while GLP-1 lowers it by stimulating insulin secretion, suppressing glucagon secretion, and slowing gastric emptying. This intricate interplay is fundamental to maintaining metabolic health, and the therapeutic harnessing of GLP-1 has revolutionized the management of diabetes and obesity. Understanding these peptide hormones and their mechanisms of action is key to appreciating the complex systems that govern our bodies.